BiotechTube

Hetrombopag Olamine + Hetrombopag Olamine ；Hetrombopag Olamine Placebo

Phase 3Recruiting
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Patients With Chemotherapy-Induced Thrombocytopenia

Conditions

Patients With Chemotherapy-Induced Thrombocytopenia

Trial Timeline

Feb 1, 2026 → Jun 1, 2029

NCT ID
NCT07286032

About Hetrombopag Olamine + Hetrombopag Olamine ；Hetrombopag Olamine Placebo

Hetrombopag Olamine + Hetrombopag Olamine ；Hetrombopag Olamine Placebo is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Patients With Chemotherapy-Induced Thrombocytopenia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07286032. Target conditions include Patients With Chemotherapy-Induced Thrombocytopenia.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT07286032Phase 3Recruiting

Competing Products

20 competing products in Patients With Chemotherapy-Induced Thrombocytopenia

See all competitors
ProductCompanyStageHype Score
R744 + R744Chugai PharmaceuticalPhase 3
77
R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placeboChugai PharmaceuticalPhase 3
77
R744 + Epoetin betaChugai PharmaceuticalPhase 3
77
R744 + R744Chugai PharmaceuticalPhase 3
77
R744 + R744Chugai PharmaceuticalPhase 3
77
R744Chugai PharmaceuticalPhase 3
77
PLX3397 + TemozolomideDaiichi SankyoPhase 1/2
41
FK949EAstellas PharmaPhase 1
33
roxadustatAstellas PharmaPhase 3
77
roxadustatAstellas PharmaPhase 3
77
Roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
77
ASP8825Astellas PharmaPhase 1
33
ASP015KAstellas PharmaPhase 1
33
ASP7991Astellas PharmaPhase 1
33
Roxadustat + Epoetin AlfaAstellas PharmaPhase 3
77
ATG-FAstellas PharmaApproved
85
CelecoxibAstellas PharmaPre-clinical
23
roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
77
roxadustatAstellas PharmaPhase 3
77
FK949EAstellas PharmaPhase 1
33

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85